Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Albemarle

Cincinnati Financial

Ecolab

W.W. Grainger

Lowe's

Medtronic

Nucor

Realty Income Corp

Sherwin-Williams

Stanley Black & Decker

Sysco

Target

T. Rowe Price Group

V.F.

West Pharmaceutical Services

NOBL fell 2.78% in August which brings the Funds return for the year to a loss of 9.16%. Thus far, through September 23rd, the dividend aristocrat ETF is down 6.71%, bringing its year-to-date return to -15.25%.

My Best Dividend Aristocrats For October 2022

American Express

Home Depot

JPMorgan Chase & Co

Merck

Procter & Gamble

While investors might not desire anything less than the most exciting investment opportunities following the wild ride last year, 2022 may be the moment for Dow sleeper stocks to buy. After all, the companies listed in the Dow 30 didn't get there as part of a fly-by-night operation.

7 Dow Sleeper Stocks to Buy Before Wall Street Wakes Up

Innovative Industrial Properties

Intel

These rock-solid income stocks, with yields ranging from 5% to 7%, can pad aged investors' pocketbooks while making them richer.

3 Ideal High-Yield Dividend Stocks for Retirees That Can Turn $350,000 Into $1 Million by 2030

Sales contributions from Walgreens Boots' (WBA) newly-formed Walgreens Health segment instill investors' optimism.

Walgreens Boots' (WBA) Product Expansion Aids Amid Rivalry

Walgreens Boots Alliance is accelerating its plans for full ownership of Shields Health Solutions, paying $1.37 billion to acquire the remaining 30% stake in the company.

Walgreens to Pay $1.37B for Full Ownership of Shields Health

Shares of Walgreens Boots Alliance Inc. WBA, -0.44% shed 0.3% toward a near two-year low in midday trading Tuesday, after the drug store services company said it would spend $1.37 billion to buy the remaining 30% stake in specialty pharmacy company Shields Health Solutions that it didn't already won. Walgreens expects the latest purchase to close by the end of 2022.

Walgreens stock falls toward near 2-year low, to pay $1.4 billion for remaining stake in Shields Health

Walgreens Boots Alliance is buying the rest of Shields Health Solutions it doesn't already own for $1.37 billion.

Walgreens To Buy The Rest Of Shields Specialty Pharmacy For $1.37 Billion

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the acceleration of its plans for full ownership of Shields Health Solutions (Shields), which is delivering strong financial performance, clinical excellence and value-add contributions to WBA's business. WBA has entered into a definitive agreement to acquire the remaining 30% stake (approximately 35% on a fully-diluted basis) for approximately $1.37 billion, which is based on the exit multiple agreed

Walgreens Boots Alliance Accelerates Full Acquisition of High-Performing Shields Health Solutions

CHICAGO--(BUSINESS WIRE)--MATTER, the premier healthcare incubator and innovation hub, has launched 51 Labs, an accelerator focused on women+'s health. The name stems from the fact that women+ are 51 percent of the population.1 The inaugural year's program is focused on menopausal transition and includes partners Astellas Pharma US, Walgreens, Parkview Health and University of Chicago Medicine. Women+'s health has long been underfunded and under-innovated, given the scale of the needs and oppor

MATTER launches 51 Labs accelerator to advance women+'s health innovation

Blackstone Group

Kinder Morgan

W. P. Carey

With stock prices sliding, dividend yields are rising, enabling investors to generate more income from new investments.

5 Dividend Stocks Yielding Over 5% to Boost Your Passive Income This September

DEERFIELD, Ill.--(BUSINESS WIRE)--WBA will release its fourth quarter and fiscal 2022 earnings results at 7 a.m. Eastern time Thursday, Oct. 13, 2022.

Walgreens Boots Alliance Schedules Fourth Quarter and Fiscal Year 2022 Earnings Announcement for October 13, 2022

AbbVie

Amcor Plc

Air Products and Chemicals

Franklin Resources

Caterpillar

Federal Realty Investment Trust

Leggett & Platt

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com/Investing. 65 Aristocrats screened as of September 8, 2022 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 16.54%-36.34% topped by VFC & SWK.

4 S&P 500 Dividend Aristocrat Dogs To Buy, 1 To Watch

Pfizer

If you want to secure a decent yield, it can pay to buy shares of strong companies dealing with short-term problems.

Want Passive Income? Buy These 2 Beaten-Down Dividend Stocks

Pharmacy giant Walgreens stock is now near 10-year lows.

Has This Beaten-Down Dividend Stock Become a No-Brainer Buy?

DEERFIELD, Ill.--(BUSINESS WIRE)--WBA strengthens tech leadership to deliver even further on the future of healthcare.

Walgreens Boots Alliance Strengthens Tech Leadership to Deliver Even Further on the Future of Healthcare

With the average dividend of the S&P 500 at 1.6%, investors in retirement may feel that there are few places to find safe income in the stock market, observes asserts Ben Reynolds; here, the editor of Sure Dividend and contributor to MoneyShow.com reviews 5 favorite stocks for retirees.

Kings & Aristocrats: 5 Retirement Favorites

Kroger

Walmart

U.S. pharmacy operators Walgreens Boots Alliance, Walmart Inc and Kroger Co on Tuesday faced off against the state of New Mexico in the latest trial over their alleged role in the U.S. opioid epidemic, following recent high-profile losses for pharmacies in other lawsuits.

Pharmacy operators Walmart, Walgreens, Kroger begin opioid trial in New Mexico

Amgen

Cisco Systems

Should investors be watching these dividend paying stocks this week?

Best Dividend Stocks To Invest In Right Now? 4 For Your List

Walgreens is looking cheap after declining by -33.53% YTD and pushing its price to FCF multiple to 8.86x. Walgreens has created value for shareholders despite its falling share price as its repurchased more than 20% of its shares outstanding since 2015.

Walgreens Dividend Is Now Yielding 5.45% And Is Looking Inexpensive

Walgreens Boots Alliance, Inc. is the holding company that owns the pharmacy chains Walgreens and Boots, as well as some smaller pharma manufacturers and distributors. Trading at a one-year forward P/E of less than x6 and a dividend yield of greater than 5%, Walgreen Boots Alliance stock is just too attractive to ignore.

Walgreens Boots Alliance: Risk/Reward Skewed To The Upside

CVS Health

As an investor initially drawn to Walgreens' dividend champ status, I begin to be concerned about the unthinkable: the possibility of a dividend cut. Its profitability has been deteriorating in the past several years and the business is facing multiple headwinds ahead.

Walgreens Vs. CVS: I'm Worried About A Dividend Cut

Walgreens suffers from weakening fundamentals in the last three years. The management team at Walgreens is working on stabilizing the business and reaching growth.

Walgreens May Be A Falling Knife, Yet Suits Income Investors

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens now offers updated COVID-19 Pfizer and Moderna boosters to eligible individuals aged 12 years and older.

Walgreens Now Offering Appointments for Updated COVID-19 Pfizer and Moderna Boosters

Salesforce

NIKE

The market has declined, but these stocks have performed much worse.

Should You Buy the Dow Jones' 4 Worst-Performing 2022 Stocks?

Resist the temptation to step into the market's most beaten-down names. They're deeply discounted for a reason.

News for Walgreens Stock (WBA)